Goldman Sachs Sees Johnson & Johnson As "Under-appreciated"

According to Goldman Sachs, Johnson & Johnson's JNJ Pharma Analyst Day reinforced Goldman's conviction in JNJ as the best new product story in the global drug sector, given its dominant positions in the largest and fastest growing categories. Goldman Sachs said that many of JNJ's new products are launching imminently and are first-in-class or a novel class – providing ample catalysts and drug launches to monitor. “We continue to see JNJ as an underappreciated Pharma pipeline story that flies under the radar, as the majority of JNJ's analyst coverage focuses on medical devices.” Johnson & Johnson closed yesterday at $65.51.